Longboard Pharmaceuticals (LBPH) just unveiled an update.
Longboard Pharmaceuticals, Inc. is poised to unveil study results on Bexicaserin’s effectiveness and safety in treating developmental and epileptic encephalopathies at the upcoming 76th Annual Meeting of the American Academy of Neurology. These findings will also be shared with investors and analysts from April 15, 2024, and will be accessible on the company’s website. This information, although not legally filed, provides valuable insights for those tracking Longboard’s progress and potential impact on the market.
See more insights into LBPH stock on TipRanks’ Stock Analysis page.
